Purpose: ABTL0812 is a novel first-in-class, small molecule which showed antiproliferative effect on tumor cells in phenotypic assays. Here we describe the mechanism of action of this antitumor drug, which is currently in clinical development.
Introduction
The PI3K/AKT/mTORC1 (mTOR complex-1) signaling pathway drives signals from ligand-stimulated receptor tyrosine kinases (RTK) to proteins that control cell metabolism, growth, size, survival, and angiogenesis (1) . In response to growth or survival factors, phosphorylated RTKs activate PI3K, which generates the phosphatidylinositol 3,4,5-trisphosphate (PIP3) second messenger and allows the recruitment of protein kinase Akt to the cellular membrane. Akt binds PIP3 through its PH domain, resulting in a conformational change that enables its activation through phosphorylation of two critical residues: Thr308 at the T-loop of the kinase domain by the phosphoinositide-dependent kinase-1 (PDK1), and Ser473 at the C-terminal hydrophobic motif by mTOR complex-2 (mTORC2; refs. 2, 3) . Active Akt phosphorylates a plethora of substrates that regulate cell survival and metabolism, and also cell growth through subsequent activation of mTORC1. Akt phosphorylation of PRAS40 and TSC2 leads to activation of mTORC1, which promotes protein translation and synthesis by phosphorylating ribosomal S6-Kinase (S6K) and the elongation factor 4EBP-1 (4) .
Human cancer is very often associated with activation of the PI3K/Akt/mTORC1 pathway, mainly due to overexpression or activating mutations of RTKs and PI3K, to deletions/mutations of the PIP3 phosphatase PTEN and to amplification of Akt (3, 5) . These types of tumors are hypersensitive to inhibition of each of the components of the PI3K/Akt/mTORC1 axis, and therefore major efforts have been taken to develop inhibitors of this signaling pathway (6) . Akt acts as a central node of this pathway, and hyperactivated Akt is a common feature observed in human solid tumors (3, 5) . Therefore, Akt has been proposed as an interesting target in cancer therapy. Two classes of Akt inhibitors are now in clinical development: ATP-competitive inhibitors (such as GSK690693) which target active Akt, and allosteric inhibitors (such as MK-2206 and perifosine, currently in phase II and phase III clinical trials, respectively) that by binding the PH domain of Akt prevent its activation by upstream kinases (3, 7) .
Here we present ABTL0812, a first-in-class molecule with antitumor activity which is currently in phase I/Ib clinical trials in patients with advanced solid tumors. We provide evidences showing that ABTL0812 inhibits Akt phosphorylation by upregulating the expression of TRIB3, a pseudokinase that binds and inhibits Akt, leading to mTORC1 inhibition and autophagy-mediated cell death.
Methods
Cell culture, viability assay, transfection, and lysis Human cancer cell lines were purchased from ATCC (2008; ATCC-authentication by isoenzymes analysis). Atg5 þ/þ and Atg5 À/À T-large antigen-transformed MEFs were donated by Dr.
Mizushima (Tokyo Medical University, Tokyo, Japan). TRB3
and TRB3 À/À RasV12/E1A-transformed Mouse embryonic fibroblasts (MEF) have been described before (8) . Cell lines were cultured as recommended and transfected using Lipofectamine-2000. Cell viability was determined by the MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium Blue) reduction assay (9) . Cells were lysed in ice-cold RIPA buffer supplemented with 1 mmol/L sodium-orthovanadate, 50 mmol/L NaF, and 5 mmol/L sodium-pyrophosphate, sonicated and stored at À20 C.
Immunoblotting and immunoprecipitation
Immunoblot analyses were performed following standard procedures as described (10) and antibodies listed in the Supplementary Table S1 . Akt was immunoprecipitated following the protocol previously described (11) .
Transmission electron microscopy
Cells treated with ABTL0812 or vehicle (ethanol) were processed as described before (12) . Pellets were embedded in Eponate-12TM resin (Ted Pella). Ultrathin (70-nm thick) sections were contrasted with uranyl-acetate and lead citrate solutions, and visualized in transmission electron microscope (Jeol JEM-1400) equipped with a CCD-GATAN-ES1000W Erlangshen camera.
Xenograft models
For A549 model, athymic female nude mice (n ¼ 5 per group) were injected subcutaneously with 5 Â 10 6 cells in each flank. When tumors reached 80 to 100 mm 3 , mice were randomly distributed into treatment groups and administered the corresponding treatments. ABTL0812 was administered by oral gavage at 120 mg/kg every day. Docetaxel was administered by intraperitoneal route at 15 mg/kg once a week. MiaPaCa-2 cells were injected in athymic male mice (n ¼ 5 per group) with 10 Â 10 6 cells in one flank. When tumors reached 80 to 160 mm 3 , mice were randomly distributed and treated with vehicle or ABTL0812 120 mg/kg by oral gavage five times per week. Tumor volumes were measured as (length Â width 2 )/2, twice a week. All procedures involving animal were performed with the approval of the Hospital Clinic Animal Experimentation Committee, according to Spanish official regulations.
Pharmacokinetics of ABTL0812 in mice and rats
ABTL0812 was orally (gavage, 100 mg/kg) and intravenously (10 mg/kg) administered to male CD-1 mice. ABTL0812 was quantified in plasma by validated LC/MS-MS methods and pharmacokinetic parameters were calculated with WinNonlin software.
Clinical trial and isolation of PBMC from patients
ABTL0812 is currently in clinical evaluation in a phase I/Ib trial in patients with advanced solid tumors. This study was approved by the local Ethics Committee of the Hospital Clinic Barcelona and the Spanish Agency of Medicines. The trial is registered at www.clinicaltrials.gov (NCT02201823). ABTL0812 was administered daily by the oral route at a dose of 1,000 mg twice daily for a period of 28 days. Blood samples for biomarker study were obtained by venipuncture before and after ABTL0812 treatment. PBMC were isolated by Ficoll (GE-Healthcare) density centrifugation, lysed in RIPA buffer, sonicated, and stored at À20 C.
Statistical analysis
All in vitro data were assessed using one-way ANOVA followed by Bonferroni multiple comparison test. Tumor volumes of mice were compared using the ANOVA followed by t test. Statistical significance between the groups was assessed with the log-rank test (GraphPad). Levels of statistical significance were set at P 0.05.
Results

ABTL0812 has anticancer activity in vitro and in vivo
A novel class of chemically modified lipid-derived small molecules was selected on the basis of two phenotypic assays: antiproliferative effect on tumor cells and low toxicity after high doses
Translational Relevance
Hyperactivation of the Akt/mTORC1 axis is commonly observed in many human cancers and blocking this pathway is an important anticancer strategy. Inhibition of Akt is a valid target for anticancer therapy and several AKT inhibitors are under clinical development. We present ABTL0812, a first-inclass small molecule with a unique mechanism of action. In cells and tumor xenografts models, ABTL0812 induces upregulation of TRIB3 pseudokinase. TRIB3 binds Akt, preventing its activation by upstream kinases and resulting in an effective inhibition of the Akt/mTORC1 axis and in autophagy-mediated cancer cell death. ABTL0812 is currently in phase I/Ib firstin-human clinical trial in patients with advance solid tumors. Preliminary results show that ABTL0812 also induces Akt inhibition in humans. These evidences, together with a very low toxicity and high tolerability, support further development of ABTL0812. administration in rodents. From this class, ABTL0812 was selected for further preclinical development. The formula for ABTL0812 is 2-hydroxylinoleic acid (Fig. 1A) .
ABTL0812 reduced viability of different human cancer cell lines tested with IC 50 values of 20 to 60 mmol/L (Fig. 1B) . Real-time cell analyses further demonstrated the antiproliferative effect of ABTL0812 ( Supplementary Fig. S1 ). ABTL0812 also induced cell death, which was confirmed by propidium iodide staining (Supplementary Fig. S2 ). Importantly, ABTL0812 induced death in cancer cells but not in normal cells. Compared with LN-18 glioblastoma cells, primary astrocytes were resistant to ABTL0812 treatment at the highest ABTL0812 concentration tested (200 mmol/L; Fig. 1C ).
To address ABTL0812 pharmacokinetics, we administered the compound to mice by oral and intravenous routes. ABTL0812 showed an excellent bioavailability by oral route (F:103%), with rapid oral absorption (t max :30 minutes), high pick concentrations (C max :2.0 mg/mL), and wide volume of distribution (Vss:10.4 L/kg). Clearance was also high (Cl: 82 mL/minute/kg). Overall, the compound was well tolerated and animals appeared healthy with no clinical signs of distress, local or systemic toxicity.
To test the efficacy of ABTL0812 in inhibiting tumor growth in vivo, we used human lung and pancreatic xenograft models. A549 human lung cancer xenografts of nude mice were treated with ABTL0812 or the standard-of-care docetaxel. ABTL0812 inhibited tumor progression with an efficacy similar to docetaxel (Fig. 1D) . Moreover, ABTL0812 lacked the toxic effects observed for docetaxel, as shown by body weight measurements. Similarly, ABTL0812 also inhibited the growth of MiaPaCa-2 human pancreatic cancer xenografts in nude mice, without affecting body weight (Fig. 1E ).
ABTL0812 induces autophagy-mediated cell death
Next, we investigated the type of cell death induced by ABTL0812 in A549 and MiaPaCa-2 cells. ABTL0812 did not induce nuclear fragmentation/condensation, or caspase-3 activation ( Supplementary Fig. S3 ). Treatment with staurosporine resulted in typical features of apoptosis, showing that A549 and MiaPaCa-2 cells are apoptosis competent. These results indicate that ABTL0812 fails to induce apoptosis. In turn, several evidences indicated that ABTL0812-induced cell death is mediated by autophagy.
Two of the hallmarks of autophagy are the conversion of the soluble form of LC3 to a lipidated form associated to autophagosomes (LC3-II), and the elimination of autophagosome cargo proteins such as p62 (13) . In A549 and MiaPaCa-2 cells, ABTL0812 induced the appearance of LC3-II and a decrease on p62 protein in a concentration-dependent manner ( Fig. 2A) . We also observed the occurrence of LC3-positive dots in cells treated with ABTL0812, which indicates association to autophagosomes ( Supplementary Fig. S4 ). Electron microscopy analysis of ABTL0812-treated A549 and MiaPaCa-2 cells revealed the presence of double membrane vacuolar structures with the morphologic features of autophagosomes (Fig. 2B) . Moreover, ABTL0812 also induced hallmarks of autophagy in vivo, as tumors from A549 xenograft mice treated with ABTL0812 showed an increase in LC3-II levels, compared with mice treated with vehicle ( Fig. 2C) .
Next, we investigated the role of autophagy in the cell death induced by ABTL0812. Pharmacologic inhibition of autophagy was achieved by treating cells with a combination of the lysosomal protease inhibitors E64d and Pepstatin-A (PA) that block the final step of autolysosomal degradation. Treatment of cells with E64dþPA prevented ABTL0812-induced cell death and resulted in an enhancement of LC3-II accumulation in cells treated with ABTL0812 (Fig. 2D ), indicating that ABTL0812 induces dynamic autophagy in cancer cells. Finally, we evaluated the activity of ABTL0812 in oncogene-transformed embryonic fibroblasts derived from Atg5 À/À (autophagy-deficient) mice.
Atg5 is an essential protein for autophagosome formation (14) . Transformed Atg5 À/À MEF cells were more resistant to ABTL0812-induced cell death than transformed Atg5 þ/þ MEF cells, and did not activate autophagy in response to ABTL0812 treatment ( Fig. 2E ). Taken together, these results show that autophagy mediates ABTL0812-induced cancer cell death.
ABTL0812 inhibits the Akt/mTOR axis
Autophagy induction is often consequential to the inhibition of mTOR signaling, as mTORC1 acts as a central regulator in autophagy induction (15) . We therefore investigated whether ABTL0812-induced autophagy and cancer cell death occurred via mTORC1 inhibition, by measuring levels of activation of components of the Akt/mTORC1 signaling pathway. A549 and MiaPaCa-2 cells showed measurable phosphorylation levels for all the proteins of Akt/mTORC1 axis in basal conditions. ABTL0812 treatment reduced phosphorylation of ribosomal-S6 kinase and of ribosomal-S6 protein (a well-established S6K substrate) in a concentration-dependent manner (Fig. 3) .
Protein kinase Akt modulates the activation of mTORC1 by phosphorylating and inactivating the TSC2 and PRAS40 proteins that act as repressors of mTORC1 activity (1). Thus, Akt inhibition results in impaired mTORC1 activity and activation of autophagy. ABTL0812 induced Akt inhibition in A549 and MiaPaCa-2 cells in a dose-dependent manner, by reducing phosphorylation of the two critical residues involved in Akt activation, Thr308 and Ser473. Consequently, ABTL0812 also reduced phosphorylation of the Akt substrates PRAS40 and TSC2 (Fig. 3) . These results show that ABTL0812 induced inhibition of the Akt/mTORC1 axis in cancer cells.
ABTL0812 binds and induces PPARa and PPARg transcriptional activities, which mediate in ABTL0812-induced cancer cell death
To identify the molecular targets of ABTL0812, we performed in silico high-throughput screening comparing ABTL0812 chemical structure against the ChEMBL15 database (https://www.ebi.ac. uk/chembldb/), following the similar property and active analog principles (16) . This approach allowed the identification of several ABTL0812 target candidates, including PPARa and PPARg.
(Continued.) C, LN-18 glioblastoma cells or primary rat astrocytes were incubated with ABTL0812, and 48 hours later cell viability was monitored by MTT assays. Similar results were obtained in three separate determinations. D and E, ABTL0812 inhibits tumor growth in lung (D) and pancreatic (E) cancer xenograft models. Athymic nude mice injected with A549 or MiaPaCa-2 cells were treated with vehicle or ABTL0812 by oral gavage. Docetaxel was administered by intraperitoneal injection. Tumor growth and weight variation curves are shown. Results are the mean AE SD of five mice in each group. Because of toxicity in the docetaxel treatment, only two mice were left at day 25 (n ¼ 2) and one after day 28 (n ¼ 1). Ã , P < 0.05; ÃÃ , P < 0.01. Figure 4A shows the molecular model of ABTL0812 into the ligand-binding pocket of PPARg. In this model, ABTL0812 may bind the PPARg ligand-binding domain (LBD) through its carboxylate group, which forms hydrogen bonds with the side of key amino acid residues (Ser289, His323, Tyr473, and His449), as it has been shown for other PPARg agonists such as rosiglitazone (17) . The 2-hydroxyl group of ABTL0812 may also form hydrogen bonds with residues Cys285 and Ser289, which are also conserved in the PPARa LBD. This molecular model proposes that ABTL0812 might establish interactions similar to the specific PPARg agonist rosiglitazone, thus predicting that ABTL0812 could act as PPAR agonist. Indeed, in vitro radioligand displacement assays using purified proteins showed that ABTL0812 binds PPARa and PPARg ligand-binding pockets with K i values of 7.1 mmol/L and 4.7 mmol/L, respectively (Supplementary Fig. S5 ).
Next, we investigated the functional relevance of this interaction, performing luciferase-based gene reporter assays in cells transfected with a PPAR-response element (PPRE) fused to luciferase construct. In A549 and MiaPaCa-2, ABTL0812 induced approximately 5-fold PPAR transcriptional activity, similarly to the specific agonists WY-14643 (PPARa) or rosiglitazone (PPARg; Supplementary Fig. S6 ). To determine whether ABTL0812-induced PPAR activation was mediated by the PPAR isoforms a and/or g, we performed analogous gene reporter assays in cells transiently transfected with plasmids encoding each isoform. ABTL0812-induced PPAR transcriptional activity was higher in cells overexpressing PPARa or PPARg proteins, compared with those having the endogenous proteins only (Fig. 4B) , suggesting that ABTL0812 functionally interacts with both receptors in cells.
Finally, we performed cell viability assays in the presence of PPARa/g antagonists. In A549 and MiaPaCa-2 cells, preincubation with PPARa antagonist GW6471 or PPARg antagonist GW9662 prevented cell death induced by ABTL0812 (Fig. 4C) , indicating that PPAR receptors mediate in ABTL0812-induced cell death.
ABTL0812 activates PPARa-and PPARg-dependent expression of TRIB3
Koo and colleagues showed that PPARs regulate the expression of the pseudokinase Tribbles 3 (TRIB3), through binding a PPARresponsive element sequence within the TRIB3 promoter (18) . Other authors have shown that TRIB3 can interact with Akt, preventing its activation by upstream kinases and resulting in an inactive form of Akt (8, 19) . Thus, we hypothesized that ABTL0812 could inhibit Akt (and downstream mTORC1) by upregulating TRIB3 via PPARa/g activation. In A549 and MiaPaCa-2 cells, ABTL0812 induced a quick and robust increase in TRIB3 protein levels after 12 hours of treatment (Fig. 5A) , that correlated with an increase in gene transcription (Fig. 5B ) and qPCR-measured TRIB3 mRNA levels (Fig. 5C ). Although we cannot discard an effect of ABTL0812 on TRIB3 stability, these results indicate that ABTL0812 upregulates TRIB3 gene transcription. Furthermore, treatment with PPARa and/or PPARg inhibitors GW6471 and GW9662, respectively, completely abolished the ABTL0812-induced upregulation of TRIB3 gene expression (Fig. 5C) . Interestingly, treatment with either PPARa or PPARg agonists resulted in increased TRIB3 expression and reduced Akt phosphorylation (Fig. 5D ). However, it was necessary to combine treatment with both agonists to obtain similar levels of inhibition of Akt (phospho-PRAS40) and mTORC1 activities (phospho-S6K and phospho-S6) than those induced by ABTL0812. Altogether, our results demonstrate that ABTL0812 induces TRIB3 gene expression via activation of PPARa and PPARg activities.
ABTL0812 inhibits Akt and mTORC1 via TRIB3
To investigate the role of upregulated TRIB3 on Akt activation, we overexpressed increasing amounts of TRIB3 in A549 and MiaPaCa-2 cells. We observed reduced phosphorylation of Akt and Akt substrate PRAS40 that inversely correlated with TRIB3 expression (Fig. 6A) . This was probably due to a TRIB3-Akt physical interaction, because ABTL0812 treatment increased the amount of Akt coimmunoprecipitated with TRIB3 (Fig. 6B) . Moreover, unlike wild-type transformed MEF, TRIB3-deficient MEF cells did not show Akt (Ser473) or mTORC1 (pS6) inhibition, or induction of autophagy (LC3-II marker) in response to ABTL0812 treatment (Fig. 6C) . Cell viability assays showed that TRIB3-deficient MEFs are resistant to ABTL0812-induced cell death, unlike wild-type transformed MEFs (Fig. 6D) . These results support a pivotal role of TRIB3 on the impairment of the Akt/ mTORC1 axis and on the autophagy-mediated cancer cell death observed in response to ABTL0812 treatment.
ABTL0812 induces TRIB3 upregulation and Akt inhibition in vivo
To determine the in vivo relevance of our findings, we next investigated the effect of ABTL0812 in A549 human lung and MiaPaCa-2 human pancreatic cancer xenografted mice (Fig. 1C  and D) . Immunohistochemical and immunoblotting analyses showed that ABTL0812-induced upregulation of TRIB3 protein and inhibition of Akt phosphorylation (Ser473) in A549 and MiaPaCa-2 tumors (Fig. 6E) . These data, together with that presented in Fig. 2 showing that ABTL0812 induces autophagy in A549 xenografts, suggest that the antitumor activity of ABTL0812 in vivo relies on inhibition of Akt and induction of autophagymediated cell death.
Akt phosphorylation is a pharmacodynamic marker in patients treated with ABTL0812
Finally, we evaluated the activity of ABTL0812 in some patients included in phase I/Ib clinical trials (NCT02201823), monitoring Akt phosphorylation levels in PBMCs. We collected blood samples, pretreatment and at different days of chronic treatment with 1,000 mg of ABTL0812, a dose that was safe and well tolerated (preliminary data not shown). Our preliminary results show that treatment with ABTL0812 resulted in a marked reduction on Akt phosphorylation in PBMCs from 3 patients (Fig. 6F) . We could not detect TRIB3 protein in PBMCs, using commercially available anti-TRIB3 antibodies. However, parallel qPCR analysis showed a significant increase in TRIB3 mRNA levels in human PBMCs treated in vitro with ABTL0812 ( Supplementary Fig. S7 ), thus suggesting that ABTL0812 also induces Akt inhibition in humans through upregulation of TRIB3.
Discussion
Here, we present the mechanism of action of ABTL0812, a novel and first-in-class antitumor drug which is currently in phase I/Ib clinical trials in patients with advanced solid tumors. ABTL0812 is a polyunsaturated fatty acid derivative, small molecule that induces cell death in a broad panel of cancer cell lines, whereas it does not affect cell viability of nontumorogenic cells. ABTL0812 also inhibits tumor growth in human lung and pancreatic tumor xenografts. Herein, we elucidated a novel cell signaling pathway through which ABTL0812 induces autophagic cell death. We showed that ABTL0812 induces upregulation of the TRIB3 pseudokinase through activation of PPARa and PPARg transcription factors. Upregulated TRIB3 binds to Akt and prevents its activation by PDK1 and mTORC2 upstream kinases, resulting in inhibition of the Akt/mTORC1 axis and, therefore, autophagy-mediated cell death (Fig. 6G) .
Autophagy is an essential process that consists of selective degradation of cellular components, assuring the maintenance of cellular homeostasis via lysosomal degradation pathways (13) . The role of autophagy in cancer is still far from clear, as it can act as a tumor suppressor and tumor promoter, depending on tumor type, stage, and genetic context, as well as on the duration and strength of the triggering stimuli (15, 20) . Our results demonstrate that ABTL0812 induces autophagy-mediated cancer cell death in vitro and in vivo, without activating cellular apoptosis. These results are in agreement with those reporting that polyunsaturated fatty acid and derivatives exert their antiproliferative action through activation of autophagy (21) (22) (23) .
The majority of current anticancer treatments activate apoptosis, and resistance to chemotherapy is a major challenge in cancer (24) . Autophagy-mediated cell death has emerged as an alternative to kill cancer cells without inducing resistance to apoptosis inducer drugs (25) . mTORC1 plays a central role in regulating cellular autophagy, and mTORC1 inhibitors induce autophagymediated cell death in many systems, such as AZD8055 in hepatocellular carcinoma (26) or Ku0063794 and temsirolimus in renal carcinoma (27) . On the other hand, mTORC1 activation ABTL0812-evoked TRIB3 upregulation inhibits Akt activity in vitro and in vivo. A, cells transfected with empty or increasing amounts of a plasmid encoding human-TRIB3 were lysed and levels of proteins monitored by immunoblotting. B, immunoprecipitation of Akt from MiaPaCa-2 lysates after treatment with vehicle or ABTL0812 for 24 hours. Top, levels of Akt and TRIB3 in the immunoprecipitates. C, wild-type and TRIB3-KO MEF cells were treated with ABTL0812 for 24 hours, and levels of the indicated proteins were analyzed by immunoblotting. D, wild-type and TRIB3-KO MEFs were treated with ABTL0812 for 24 hours, and cell viability measured by MTT analysis. Values are the mean AE SD of three different determinations.
ÃÃÃ P < 0.001 from TRIB3 wt. E, A549 and MiaPaCa-2 tumors were collected after sacrifice, and TRIB3 was evaluated by immunohistochemical analysis (left; scale bars: 100 mm). Levels of phospho-Akt(Ser473) were evaluated in total protein extracts, by immunoblotting (right). Histograms show the corresponding quantifications. Ã , P < 0.01; ÃÃ , P < 0.005; ÃÃÃ , P < 0.001 from vehicle-treated tumors. F, phospho-Akt and Akt levels in PBMCs from patients before (day 0) or after 1,000 mg bid ABTL0812 oral chronic treatment. Protein extracts were analyzed by immunoblotting for phospho-Akt-Ser473 and total Akt. Upper graphs show the quantification of levels of phospho-Akt normalized with Akt protein, estimated by densitometric analysis (day 1 ¼ 100%) . G, a model showing the mechanism of action of ABTL0812.
is frequently associated with resistance to antitumor drugs (6) . As ABTL0812 is a potent inhibitor of the Akt/mTORC1 axis, its administration in combination with standard chemotherapeutic drugs might prove effective in therapy-resistant or apoptosisrefractory tumor. This has been shown for the mTORC1 inhibitor everolimus (RAD001), which sensitizes papillary thyroid cancer cells to treatment with doxorubicin by an autophagy-mediated mechanism (28) .
Here we present in vitro and in vivo evidences showing that ABTL0812 binds to and activates PPARa and PPARg transcriptional activities, and that pharmacologic inhibition of both receptors prevents ABTL0812-induced cancer cell death, suggesting that PPARa/g are the primary molecular targets of ABTL0812 in the cell. PPARs are nuclear receptors that heterodimerize with the retinoid-X receptors to modulate gene transcription. Mammalian cell expresses three PPAR isoforms, PPARa, PPARb/d, and PPARg (29) . Using an in silico analysis, we identified PPARa and PPARg as targets of ABTL0812, but not PPARb/d. Several authors have shown that polyunsaturated and derivative long fatty acids activate PPARs transcriptional activities (21, 30) . Interestingly, the docking experiments performed in our study show that the a-hydroxyl group in ABTL0812 forms two extra hydrogen bonds with the critical residues Cys285/Ser289 in PPARg LBD (also conserved in the PPARa LBD), compared with the nonhydroxylated linoleic acid. Accordingly, ABTL0812 showed higher PPARg agonistic activity ( PPARs regulate the expression of many genes involved in glucose and lipid metabolism (29, 31) . Interestingly, activation of PPARg reduces cell proliferation and invasion, and enhances apoptosis in different cancer models such as breast and hepatocarcinoma (21, 32) , whereas activation of PPARa inhibits tumor growth and angiogenesis in mouse models (33) (34) (35) . Therefore, activators of PPARa or PPARg have been proposed as anticancer drugs, and specific synthetic PPARa or PPARg agonists are in clinical trials for treating cancer, such as the PPARg agonist efatutazone or the PPARa agonist fenofibrate, in patients with liposarcoma (NTC02249949) or multiple myeloma (NCT01965834), respectively. ABTL0812, by activating PPARa and PPARg, might well synergize the anticancer activity of each receptor. Importantly, single treatment of the cancer cells used in our study with either PPARa or PPARg agonist induced partial inhibition of mTORC1 activity, whereas combined treatment with both agonists resulted in a robust mTORC1 inhibition, similar to that obtained for ABTL0812 treatment (Fig. 5D) . Given the fact that a new generation of dual PPARa/g agonists has shown promising anticancer activity (i.e., TZD18 in breast cancer; ref. 36 ), it will be of interest to investigate whether PPARa/g mechanism of action also involves inhibition of the Akt/mTORC1 axis.
Our most striking result is the observation that upregulation of Tribbles pseudokinase-3, through activation of PPARa/g receptors, plays a crucial role in the anticancer activity of ABTL0812. TRIB3 is a highly conserved protein which lacks critical catalytic residues for binding ATP and therefore lacks kinase activity (37) . Together with TRIB1 and TRIB2 proteins, TRIB3 define the Tribbles subfamily of pseudokinases, which was first described in Drosophila as regulators of cell proliferation and migration during development (38) . As it happens for other pseudokinases, TRIB3 exerts its function in the cell interacting with several proteins, such as the transcription factors SMAD3 (39) and ATF-4 (40), or members of the MAPK family (41) . Of note, few authors have shown that TRIB3 can interact with Akt, preventing its phosphorylation by upstream kinases and resulting in suppression of the insulin pathway (16, 19, 42) . Here we show that ABTL0812-evoked TRIB3 binds Akt, and that TRIB3 overexpression in cells resulted in Akt inhibition. Moreover, we also found that treatment with ABTL0812 enhances the interaction between TRIB3 and Akt, in line with previous data obtained in glioma cells and oncogenetransformed MEFs, where a similar increase in TRIB3 levels and TRIB3-Akt interaction occur upon exposure to D 9 -tetrahydrocannabinol (THC; refs. 12). TRIB3 interacts more strongly with inactive/dephosphorylated Akt than active Akt (M. S., unpublished results), therefore it is likely that overexpressed TRIB3 could trap the inactive form of Akt, preventing its activation/ phosphorylation by upstream kinases. Whether TRIB3 masks the phosphorylatable residues in Akt (Thr308 and Ser473), induces a conformational change that impairs recognition by upstream kinases PDK1 and mTORC2, or hampers the binding of the Akt PH domain to PIP3 remains to be clarified. On the other hand, it is also likely that, in addition to changes in TRIB3 protein levels, there could exist additional mechanisms involved in regulating the interaction of TRIB3 with its protein targets, and specifically with Akt. Posttranslational modifications of TRIB3, yet to be described, and/or changes in the interaction with other members of the Tribbles family that participate in modulating these interactions, are two plausible possibilities that are currently investigated in our laboratories.
Our results indicate that TRIB3 plays a central role in the mechanism of action of ABTL0812, as it has been proposed for other antitumoral drugs, such as THC in glioma and hepatocellular carcinoma tumors (43, 44) or salinomycin in lung cancer cells (45) . Interestingly, these drugs also induce autophagy, as it does ABTL0812, suggesting that TRIB3 upregulation effectively provokes a robust inhibition of the Akt/mTORC1 axis in vivo. THC and salinomycin exert their action by stimulation of endoplasmic reticulum stress and then activating ATF4/CHOP transcription factors that regulate TRIB3 gene. In our study, we identify a new route that links PPARa/g activation, inhibition of Akt/mTORC1 via TRIB3 and cancer cell death.
There are contradictory reports in the literature regarding the role of TRIB3 in human cancer. Some laboratories reported elevated TRIB3 mRNA levels which correlated with bad prognosis in colorectal cancer (46) and breast cancer patients (47) . On the other hand, high TRIB3 protein levels have been associated with good prognosis sensitivity to radiotherapy in breast cancer patients (48) . As TRIB3 is a very stable protein (49) , the discrepancies observed between TRIB3 mRNA and protein levels in human breast cancer prognosis might be due to posttranslational modifications, still to be described, that might modulate the ability of TRIB3 to interact with other proteins that regulate tumor growth. In this study, however, we show that ABTL0812 treatment induces a robust increase in TRIB3 transcription and mRNA and protein levels, which correlate with cancer cell death and tumor growth inhibition. Our results are in agreement with a recent report showing that genetic inhibition of TRIB3 enhances tumorogenesis in different cancer models (8) , and support a role for TRIB3 as a tumor suppressor.
Hyperactivation of the Akt/mTORC1 axis is observed in the majority of human cancers and blocking this pathway is an important anticancer strategy (5) . We have shown here the activity of ABTL0812 in a panel of cancer cell lines that express high levels of phosphorylated/active Akt. Importantly, we have preliminary observed activity of ABTL0812 in patients. ABTL0812 treatment impaired Akt phosphorylation in PBMCs from patients included in the ongoing phase I clinical trial (Fig. 6F) . Therefore, Akt phosphorylation will be used as a surrogated pharmacodynamic biomarker, for estimating the recommended dose for the forthcoming phase II trials. We have preliminarily observed increased TRIB3 mRNA levels in human PBMCs treated with ABTL0812 ( Supplementary Fig. S7 ), suggesting that TRIB3 qPCR analysis could be also used to monitor the biologic activity of ABTL0812 in humans. Finally, and given its unique mechanism of action, it will be important to evaluate ABTL0812 in combination with standard chemotherapeutical compounds as well as with other target therapies. We foresee ABTL0812-based therapies will contribute to improve patients' treatment and quality of life.
